2-N,N-Dimethylamino-4,6-dimethoxybenzothiophene | 185415-33-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 2-N,N-Dimethylamino-4,6-dimethoxybenzothiophene
• 英文别名: 4,6-dimethoxy-N,N-dimethylbenzo[b]thiophen-2-amine；2-dimethylamino-4,6-dimethoxybenzo[b]thiophene；4,6-Dimethoxy-2-dimethylaminobenzo[b]thiophene；4,6-dimethoxy-N,N-dimethyl-1-benzothiophen-2-amine
• CAS: 185415-33-2
• 化学式: C₁₂H₁₅NO₂S
• 分子量: 237.323
• InChiKey: WYSGSRMCLOSYJG-UHFFFAOYSA-N

物化性质

• 沸点：
  373.0±37.0 °C(Predicted)
• 密度：
  1.192±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  49.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-N,N-Dimethylamino-4,6-dimethoxybenzothiophene 在 盐酸 作用下， 以 甲醇 为溶剂， 以2.87 g的产率得到4,6-dimethoxy-2,3-dihydrobenzo[b]thiophen-2-one
  参考文献：
  名称：

  互补使用弗瑞德-克来福特（Friedel-Crafts）和定向远程金属化反应合成受约束的雷洛昔芬类似物。

  摘要：

  雷洛昔芬（1）的新的受限杂环类似物2a，b和3已通过互补的定向远程金属化（DreM）/ Friedel-Crafts环化方法制备。成功地利用了亚苄基-硫代内酯重排来以高收率构建苯并噻吩13a-c。通过络合然后进行三氟甲磺酸酯化作用而导致的13a和13b选择性脱保护，得到18和23，从而使Suzuki-Miyaura与硼烷16进行有效的交叉偶联，得到联芳基19和24。用BCl（3）处理19引起分子内对位Fridel-Crafts环化和伴随的双重脱保护，以提供类似物2a，新的5,6,6,6-（C（4）SC（6）-C（6）-C（6））含硫杂环。过量的LDA暴露于25会诱导DreM环化，从而产生邻位取代的5,6,6，6-（C（4）SC（6）-C（6）-C（6））杂环类似物26的产率为70％。对13c和27的类似处理得到30，代表新颖的5,5,6,6-（C（4）SC（5）-C（6）-C（6））环系统

  DOI：

  10.1021/jo034325k
• 作为产物：
  描述：

  N,N-dimethyl 2-(2,4-dimethoxyphenyl)-2-hydroxyethanethioamide 在 甲烷磺酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 2-N,N-Dimethylamino-4,6-dimethoxybenzothiophene
  参考文献：
  名称：

  互补使用弗瑞德-克来福特（Friedel-Crafts）和定向远程金属化反应合成受约束的雷洛昔芬类似物。

  摘要：

  雷洛昔芬（1）的新的受限杂环类似物2a，b和3已通过互补的定向远程金属化（DreM）/ Friedel-Crafts环化方法制备。成功地利用了亚苄基-硫代内酯重排来以高收率构建苯并噻吩13a-c。通过络合然后进行三氟甲磺酸酯化作用而导致的13a和13b选择性脱保护，得到18和23，从而使Suzuki-Miyaura与硼烷16进行有效的交叉偶联，得到联芳基19和24。用BCl（3）处理19引起分子内对位Fridel-Crafts环化和伴随的双重脱保护，以提供类似物2a，新的5,6,6,6-（C（4）SC（6）-C（6）-C（6））含硫杂环。过量的LDA暴露于25会诱导DreM环化，从而产生邻位取代的5,6,6，6-（C（4）SC（6）-C（6）-C（6））杂环类似物26的产率为70％。对13c和27的类似处理得到30，代表新颖的5,5,6,6-（C（4）SC（5）-C（6）-C（6））环系统

  DOI：

  10.1021/jo034325k

文献信息

• Indole derivatives for the treatment of depression and anxiety
  申请人：——

  公开号：US20040006229A1

  公开（公告）日：2004-01-08

  The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine. 1

  本发明提供了以下化合物的公式（I）：这些化合物对治疗抑郁症、焦虑症，并缓解因戒烟或部分戒烟引起的症状非常有用。
• Direct Synthesis of Diverse 2-Aminobenzo[<i>b</i>]thiophenes via Palladium-Catalyzed Carbon–Sulfur Bond Formation Using Na₂S₂O₃ as the Sulfur Source
  作者：Chuanwei Hou、Qian He、Chunhao Yang

  DOI：10.1021/ol502381e

  日期：2014.10.3

  A novel and direct synthesis of various 2-aminobenzo[b]thiophenes has been developed. The reactions were catalyzed by a combination of Pd(dppf)Cl2 and dppf using odorless and cheap Na2S2O3 as the sulfur source. This strategy allowed us to synthesize important 2-aminobenzo[b]thiophene scaffold more efficiently and conveniently.

  已经开发了新颖的直接合成各种2-氨基苯并[ b ]噻吩的方法。使用无味廉价的Na 2 S 2 O 3作为硫源，通过Pd（dppf）Cl 2和dppf的组合催化反应。这种策略使我们能够更有效，更方便地合成重要的2-氨基苯并[ b ]噻吩骨架。
• Structure−Activity Relationships of Selective Estrogen Receptor Modulators:  Modifications to the 2-Arylbenzothiophene Core of Raloxifene
  作者：Timothy A. Grese、Stephen Cho、Don R. Finley、Alexander G. Godfrey、Charles D. Jones、Charles W. Lugar、Michael J. Martin、Ken Matsumoto、Lewis D. Pennington、Mark A. Winter、M. Dee Adrian、Harlan W. Cole、David E. Magee、D. Lynn Phillips、Ellen R. Rowley、Lorri L. Short、Andrew L. Glasebrook、Henry U. Bryant

  DOI：10.1021/jm9606352

  日期：1997.1.1

  The 8-arylbenzothiophene raloxifene, 1, is a selective estrogen receptor modulator which is currently under clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. A series of raloxifene analogs which contain modifications to the 2-arylbenzothiophene core have been prepared and evaluated for the ability to bind to the estrogen receptor and inhibit MCF-7 breast cancer cell proliferation in vitro. Their ability to function as tissue-selective estrogen agonists in vivo has been assayed in a short-term, ovariectomized (OVX) rat model with end points of serum cholesterol lowering, uterine weight gain, and uterine eosinophil peroxidase activity. These studies have demonstrated that (1) the 6-hydroxy and, to a lesser extent, the 4'-hydroxy substituents of raloxifene are important for receptor binding and in vitro activity, (2) small, highly electronegative 4'-substituents such as hydroxy, fluoro, and chloro are preferred both in vitro and in vivo, (3) increased steric bulk at the 4'-position leads to increased uterine stimulation in, vivo, and (4) additional substitution of the 2-aryl moiety is tolerated while additional substitution at the 4-, 5-, or 7-position of the benzothiophene results in reduced biological activity. In addition, compounds in which the 2-aryl group is replaced by alkyl, cycloalkyl, and naphthyl substituents maintain a profile of in vitro and in vivo biological activity qualitatively similar to that of raloxifene. Several novel structural variants including 2-cyclohexyl, 2-naphthyl, and 6-carbomethoxy analogs also demonstrated efficacy in preventing bone loss in a chronic OVX rat model of postmenopausal osteopenia, at doses of 0.1-10 mg/kg.
• Benzothiophene compounds, and uses and formulations thereof
  申请人：ELI LILLY AND COMPANY

  公开号：EP0819687B1

  公开（公告）日：2001-03-14
• INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY
  申请人：ELI LILLY AND COMPANY

  公开号：EP1242411B1

  公开（公告）日：2006-03-08